All In Biotech

Drug Trial Radar · NCT05265325

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

May 3, 2023

Primary completion

Feb 29, 2024

Study completion Apr 25, 2024

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Mar 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis

Conditions

  • Renal Anemia

Interventions

  • AND017 capsules TIWDrug

    Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels

  • AND017 capsules QWDrug

    Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels

  • epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilarsDrug

    Dose regimen and adjustment rules according to the USPI or SmPC or local practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 20 weeks
  2. Mean change from baseline in Hb at Week 6Time frame: Up to 5 weeks after dosing

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • US Renal Care - Pine Bluff

    Pine Bluff, Arkansas

  • North America Research Institute

    Riverside, California

  • Rocky Mountain Kidney Care

    Lone Tree, Colorado

  • Nephrology and Hypertension Specialists

    Dalton, Georgia

  • High Desert Nephrology Associates

    Gallup, New Mexico

  • Nephrology Associates of Western New York

    Cheektowaga, New York

  • Nephrology Consultants of Northwest Ohio - Toledo

    Toledo, Ohio

  • South Texas Renal Care Group - San Saba

    San Antonio, Texas

  • Clinical Advancement Center PLLC

    San Antonio, Texas

  • South Texas Renal Care Group

    San Antonio, Texas

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Xiamen Branch, Zhongshan hospital affilicated to Fudan University

    Xiamen, Fujian, China

  • Xiamen Fifth Hospital

    Xiamen, Fujian, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hunan, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China

  • Zhongshan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • Jinshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

  • First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Zigong First People's Hospital

    Zigong, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.